Evaluation of Silodosin and Pelvic Floor Muscle Training in Men With Benign Prostatic Hyperplasia and Overactive Bladder
Evaluation of Silodosin and Pelvic Floor Muscle Training in Men With Benign Prostatic Hyperplasia and Overactive Bladder
This study will evaluate the efficacy of pelvic floor muscle training in men with benign
 prostatic hyperplasia and overactive bladder treated with Silodosin.
This is a randomised-intervention, parallel, multicentre study which will evaluate the
 efficacy of pelvic floor muscle training in men with benign prostatic hyperplasia and
 overactive bladder treated with silodosin.
Inclusion Criteria:

 -  - willing to provide written informed consent

 -  men over 50 years with lower urinary tract symptoms and overactive bladder and
 benign prostatic hyperplasia

 -  persistence of overactive bladder despite 4 weeks of silodosin treatment

 -  symptoms of overactive bladder (urinary frequency and urgency with or without
 urinary incontinence) for ≥3 months prior to visit 1.

 -  willing and able to complete the 3-day voiding diary and questionnaires

 -  International Prostate Symptom Score (IPSS) score ≥8.

 -  experience an average of 8 or more micturition's per day over the 3-day diary
 period.

 -  experience an average of 2 episodes of urgency per day (grade 3 or 4) over the
 3-diary period

 Exclusion Criteria:

 Inclusion criteria:

 • - willing to provide written informed consent

 -  men over 50 years with lower urinary tract symptoms and overactive bladder and benign
 prostatic hyperplasia

 -  persistence of overactive bladder despite 4 weeks of silodosin treatment

 -  symptoms of overactive bladder (urinary frequency and urgency with or without urinary
 incontinence) for ≥3 months prior to visit 1.

 -  willing and able to complete the 3-day voiding diary and questionnaires

 -  International Prostate Symptom Score (IPSS) score ≥8.

 -  experience an average of 8 or more micturition's per day over the 3-day diary period.

 -  experience an average of 2 episodes of urgency per day (grade 3 or 4) over the 3-diary
 period

 Exclusion criteria:

 -  post-void residual volume (PVR) >200 mL

 -  evidence of Urinary Tract Infection and haematuria

 -  use anticholinergics, beta 3 mimetics within 4 weeks prior to Visit 1 and during the
 study

 -  oncological diseases of the lower urinary tract and prostate

 -  neurogenic bladder

 -  urethral strictures and bladder neck stenosis

 -  urolithiasis

 -  diabetes mellitus

 -  previous surgery of lower urinary tract

 -  stress urinary incontinence

 -  intermittent catheterisation

 -  chronic urinary tract infection

 -  previous botox treatment in the last 12 months

 -  chronic electrostimulation treatment of OAB in the last 12 months

 -  patient began or has changed a bladder training program or pelvic floor exercises less
 than 90 days before 1 visit

 -  cognitive deficits and dementia

 -  man has participated in an interventional trial within 30 days prior to Visit 1

 -  total daily urine production over 2500 mL according to voiding diary